Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CUE Cue Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: CUE
Price (delayed)
$0.768
Market cap
$47.48M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.72
Enterprise value
$33.74M
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the
Highlights
CUE's debt is down by 40% year-on-year and by 7% since the previous quarter
The EPS is up by 35% YoY and by 21% QoQ
The gross profit has soared by 69% year-on-year but it is down by 2.6% since the previous quarter
CUE's revenue has surged by 69% year-on-year but it is down by 2.6% since the previous quarter
The company's equity has shrunk by 53% YoY and by 31% QoQ
Cue Biopharma's quick ratio has decreased by 42% YoY and by 25% QoQ
Key stats
What are the main financial stats of CUE
Market
Valuations
Earnings
Shares outstanding
61.82M
Market cap
$47.48M
Enterprise value
$33.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.78
Price to sales (P/S)
4.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.63
Revenue
$9.29M
Gross profit
$9.29M
Operating income
-$41.5M
Net income
-$40.67M
EBIT
-$39.88M
EBITDA
-$37.53M
Free cash flow
-$36.3M
Per share
Balance sheet
Liquidity
EPS
-$0.72
EPS diluted
-$0.72
Free cash flow per share
-$0.64
Book value per share
$0.28
Revenue per share
$0.16
TBVPS
$0.57
Total assets
$32.19M
Total liabilities
$14.69M
Debt
$8.88M
Equity
$17.5M
Working capital
$11.45M
Debt to equity
0.51
Current ratio
1.84
Quick ratio
1.72
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
-404.1%
Gross margin
100%
Net margin
-438%
Operating margin
-446.9%
Return on assets
-93.9%
Return on equity
-172.1%
Return on invested capital
-979.4%
Return on capital employed
-215.5%
Return on sales
-429.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CUE stock price
How has the Cue Biopharma stock price performed over time
Intraday
-0.05%
1 week
2.15%
1 month
24.31%
1 year
-59.79%
YTD
-29.54%
QTD
-15.7%
Financial performance
How have Cue Biopharma's revenue and profit performed over time
Revenue
$9.29M
Gross profit
$9.29M
Operating income
-$41.5M
Net income
-$40.67M
Gross margin
100%
Net margin
-438%
The gross profit has soared by 69% year-on-year but it is down by 2.6% since the previous quarter
CUE's revenue has surged by 69% year-on-year but it is down by 2.6% since the previous quarter
CUE's net margin has surged by 53% year-on-year and by 6% since the previous quarter
Cue Biopharma's operating margin has soared by 53% YoY and by 7% from the previous quarter
Price vs fundamentals
How does CUE's price correlate with its fundamentals
Growth
What is Cue Biopharma's growth rate over time
Valuation
What is Cue Biopharma stock price valuation
P/E
N/A
P/B
2.78
P/S
4.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.63
The EPS is up by 35% YoY and by 21% QoQ
The company's equity has shrunk by 53% YoY and by 31% QoQ
The P/B is 27% below the 5-year quarterly average of 3.8
The price to sales (P/S) is 93% lower than the 5-year quarterly average of 68.8 and 41% lower than the last 4 quarters average of 7.9
CUE's revenue has surged by 69% year-on-year but it is down by 2.6% since the previous quarter
Efficiency
How efficient is Cue Biopharma business performance
Cue Biopharma's return on equity has shrunk by 53% YoY and by 10% QoQ
The ROS has soared by 52% YoY and by 6% QoQ
The ROA has contracted by 32% YoY and by 7% from the previous quarter
The ROIC has decreased by 24% QoQ
Dividends
What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CUE.
Financial health
How did Cue Biopharma financials performed over time
The total assets is 119% greater than the total liabilities
The total assets has declined by 48% year-on-year and by 28% since the previous quarter
Cue Biopharma's quick ratio has decreased by 42% YoY and by 25% QoQ
CUE's debt is 49% smaller than its equity
The company's equity has shrunk by 53% YoY and by 31% QoQ
CUE's debt is down by 40% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.